Table 1
Effect of idarubicin concentration on proliferation of human Tenon’s capsule fibroblasts. Cells of two different patients were treated in triplicate with idarubicin at concentrations ranging from 0.01 μg/ml to 20 μg/ml for 5 minutes and counted at day 2, 5, 7, and 10 after exposure. Data represent the cell count per well ×104 (mean of 6 samples (SD))
| Idarubicin concentration (μg/ml) | Days after exposure | |||
|---|---|---|---|---|
| 2 | 5 | 7 | 10 | |
| 0 | 5.5 (0.8) | 5.5 (0.6) | 7.8 (2.8) | 13.0 (0.6) |
| 0.01 | 4.7 (2.3) | 5.4 (0.6) | 7.4 (0.8) | 13.6 (1.9) |
| 0.03 | 4.1 (1.1) | 5.1 (1.0) | 7.9 (2.5) | 10.8 (1.0) |
| 0.1 | 2.5 (0.7) | 3.3 (1.2) | 3.7 (1.9) | 6.6 (3.6) |
| 0.3 | 1.8 (0.3) | 2.0 (0.2) | 1.9 (0.5) | 2.6 (2.0) |
| 1 | 1.8 (0) | 1.4 (0.7) | 1.2 (0.5) | 1.6 (0.6) |
| 2.5 | 2.1 (0.9) | 0.9 (0) | 0.8 (0.1) | 0.7 (0.2) |
| 5 | 1.6 (0.2) | 0.6 (0.4) | 0.9 (0) | 0.6 (0) |
| 10 | 1.0 (0) | 0.6 (0.1) | 0.2 (0) | 0.4 (0) |
| 20 | 0.6 (0.2) | 0.4 (0.2) | 0.3 (0.3) | 0.4 (0.2) |
